Evidence map›Paper›PMID 31517283›Full record

ArticleInternational journal of pharmaceutics: X2019

Biophysical model to predict lung delivery from a dual bronchodilator dry-powder inhaler.

Myrna B Dolovich, Andreas Kuttler, Thomas J Dimke, Omar S Usmani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics: X, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Performance Characteristics of BreezhalerClinical drug investigation · 2021
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Myrna B DolovichDepartment of Medicine, Division of Respirology, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
Andreas KuttlerNovartis Pharma AG, Basel, Switzerland.
Thomas J DimkeNovartis Pharma AG, Basel, Switzerland.
Omar S UsmaniNational Heart and Lung Institute, Imperial College London, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A biophysical lung model was designed to predict inhaled drug deposition in patients with obstructive airway disease, and quantitatively investigate sources of deposition variability. Different mouth-throat anatomies at varying simulated inhalation flows were used to calculate the lung dose of indacaterol/glycopyrronium [IND/GLY] 110/50 µg (QVA149) from the dry-powder inhaler Breezhaler

Indexed as

AIT, Alberta idealised throatAPSD, aerodynamic particle size distributionCFD, computational fluid dynamicsChronic obstructive pulmonary diseaseComputational fluid dynamicsCOPD, chronic obstructive pulmonary diseaseCT, computed tomographyDPI, dry powder inhalerDry powder inhalerFDC, fixed-dose combinationGLY, glycopyrroniumHRCT, high-resolution computed tomographyIFR, inspiratory flow rateIND, indacaterolInhaler devicesLung depositionMMAD, mass median aerodynamic diameterNGI, Next Generation ImpactorPIV, particle image velocimetrypMDI, pressurised metered dose inhalerUSP/Ph. Eur, European Union Pharmacopoeias

Identifiers

PMID31517283
PMCPMC6733285

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.